Form 4: Acumen Pharmaceuticals Director Acquires Stock Options
SEC Form 4 Filing
Director John A. Stalfort III acquired 25,000 stock options in Acumen Pharmaceuticals on June 10, 2024.
Summary
- On June 10, 2024, John A. Stalfort III, a director of Acumen Pharmaceuticals, acquired 25,000 stock options.
- The exercise price of these options is $2.62.
- The options vest on the earlier of June 10, 2025, or the 2025 annual stockholder meeting, contingent upon continuous service.
- The options expire on June 9, 2034.
- Following the transaction, Stalfort directly owns 25,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, indicating a neutral sentiment. It simply reports a transaction without expressing any positive or negative outlook.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders, allowing investors to monitor their investment.
Stakeholder Impact
- The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 06/10/2024 | Date of transaction: Director John A. Stalfort III acquired stock options. |
| 06/10/2025 | Earliest vesting date for the stock options, contingent upon continuous service. |
| 06/09/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.